Dr. Diamandis completed his combined MD/PhD and residency training in neuropathology at the University of Toronto. His graduate work focused on designing high-throughput screening platforms to chemically profile neural precursors. This research resulted in the identification of novel regulators of neural and cancer stem cell function. Following completion of his training in 2016, he was hired as a Neuropathologist at the University Health Network. Here, his research team focuses on using chemical biology, deep learning and mass spectrometry-based proteomics to resolve phenotype-level heterogeneity in different brain and glioblastoma niches.
Mol Psychiatry. 2019 Aug 23;:
NPJ Digit Med. 2019;2:28
Neuro Oncol. 2019 May 11;:
Atypical Teratoid/Rhabdoid Sellar Tumor in an Adult with a Familial History of a Germline SMARCB1 Mutation: Case Report and Review of the Literature.
World Neurosurg. 2019 Jul;127:336-345
Crit Rev Clin Lab Sci. 2019 Jan;56(1):61-73
Neurol Clin. 2018 Aug;36(3):439-447
Precision histology: how deep learning is poised to revitalize histomorphology for personalized cancer care.
NPJ Precis Oncol. 2017;1(1):22
Visualizing histopathologic deep learning classification and anomaly detection using nonlinear feature space dimensionality reduction.
BMC Bioinformatics. 2018 May 16;19(1):173
Mol Cell Proteomics. 2017 Sep;16(9):1548-1562
J Clin Oncol. 2017 Jul 20;35(21):2386-2393
Scientist, Princess Margaret Cancer Centre
Neuropathologist, University Health Network
Assistant Professor, Department of Laboratory Medicine and Pathobiology, University of Toronto